Zacks Investment Research
05 Aug 2026, 16:55 UTC · 58m ago
Should Investors Buy Boston Scientific Stock Despite Near-Term Risks?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
05 Aug 2026, 16:55 UTC · 58m ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Boston Scientific lowered its 2026 organic sales growth guidance to 5%-6% from 6.5%-8% and reduced adjusted earnings guidance to $3.28-$3.32 per share. — A direct reduction in both top-line and bottom-line guidance for a major medical device company typically triggers an immediate negative price reaction.
-0.80Boston Scientific expects global WATCHMAN sales to decline at a mid- to high-single-digit rate in the second half of 2026 due to slowing U.S. demand. — The decline of a key product franchise suggests a loss of market momentum and disrupts long-term growth projections.
-0.60The company's 2026 adjusted operating-margin expansion forecast was reduced to just 0-25 basis points. — Stagnant margin expansion indicates poor operating leverage and rising costs that erode profitability.
-0.50Continue reading
6 related stories
Top 2 movers · tap to explore
Boston Scientific is facing increased competition in the atrial fibrillation market from Medtronic's Affera/PulseSelect and Johnson & Johnson's VARIPULSE platforms. — Increased competitive intensity in a core growth area like pulsed-field ablation threatens future market share and pricing power.
-0.40Which stocks this story touches
The company lowered its 2026 outlook due to weakened demand for WATCHMAN and losses in U.S. electrophysiology market share.
Mentioned as advancing its competitive platform in the pulsed-field ablation market.
Mentioned as expanding its competitive offerings in the pulsed-field ablation market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
2h ago
